跳至主要内容
临床试验/NCT05711459
NCT05711459招募中不适用

A Prospective and Multicenter Cohort Study of Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.

Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 5,405 人开始时间: 2022年5月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
5,405
试验地点
1
主要终点
The changes in ALT level from baseline after 4 weeks treatment of bicyclol

研究概览

简要总结

The clinical trial is designed to evaluate the efficacy of bicyclol for patients with antineoplastic drug-induced liver injury and investigate factors effecting the therapeutic outcome.

详细描述

This study prospectively studied the treatment of acute drug-induced liver injury related to anti-tumor with bicyclol tablets, to provide medical evidence in clinical practice of bicyclol treating acute drug-induced liver injury. The main purpose of this study is to evaluate the clinical efficacy and outcome of bicyclol tablets in the treatment of drug-induced liver injury and analyze the bicyclol tablet's therapeutic effects in different groups including conventional chemotherapy drugs, targeted drugs, and immunosuppressants. The secondary purpose of this study is to analyze the factors influencing the prognosis and outcome of bicyclol tablets in the treatment of acute DILI.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • The acute liver injury caused by anti-tumor drugs
  • The RUCAM assessment scale ≥6
  • The liver injury must in the acute phase
  • Must be treated with bicyclol tablets
  • Must sign informed consent -

排除标准

  • This acute liver injury caused by non-anti-tumor drugs
  • Pregnant women
  • Lactating women
  • Childbearing age women are plan to conceive

研究组 & 干预措施

Liver Injury Group

Experimental

The patients have liver injuries caused by antitumor drugs.

干预措施: Bicyclol tablets (Drug)

结局指标

主要结局

The changes in ALT level from baseline after 4 weeks treatment of bicyclol

时间窗: 4 weeks

Excellence: clinical symptoms and signs disappeared, serum ALT returned to normal; Improvement: clinical symptoms disappeared (improved), serum ALT decreased more than 50% of the original value; Invalid: Failure to meet the above criteria

次要结局

  • The changes of ALT levels compared with baseline(less than 4 weeks)
  • The condition of acute liver injuries becomes the chronic liver disease(6 months)
  • The changes of AST levels compared with baseline(less than 4 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验